Eli Lilly & Co. is taking its Alzheimer’s disease research in a new direction, a move that deepens the drug maker’s efforts to find tests and treatments for the memory-robby disorder despite a costly setback last year…In 2009, the company hired Michael Hutton, a tau specialist from the Mayo Clinic, to bolster its efforts. Within the next two years, the company expects to begin testing in patients at least one molecule targeting the tangles, Dr. Skovronsky said.

Wall Street Journal by Jonathan D. Rockoff

Tags: alzheimer's disease, Eli Lilly & Co., Michael Hutton, Neurology, Research, treatment, Wall Street Journal